MarketPulse

bladder cancer

14 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada's NDV-01 Shows 76% Response Rate, Advancing Bladder Cancer Program

Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.
RLMDclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Warning Letter Over Misleading Cancer Drug Claims

ImmunityBio faces securities lawsuit after FDA warning letter over misleading Anktiva efficacy claims. Stock plunged 21%, erasing $2 billion in market value.
IBRXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Flags Cancer Drug Misleading Claims

ImmunityBio shares plunge 21% after FDA flags misleading cancer drug claims; $2B market cap erased. Securities lawsuit filed.
IBRXstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Faces Class Action Over FDA Warning on Cancer Drug Claims

ImmunityBio (IBRX) shares plunged 21% after FDA warning letter citing misleading efficacy claims about immunotherapy drug Anktiva. Class action lawsuit underway with May 26 deadline.
IBRXinvestor lossessecurities class action
BenzingaBenzinga··Vandana Singh

FDA Warns ImmunityBio Over Anktiva Cancer Claims Despite Strong 750% Sales Surge

FDA flagged ImmunityBio for unsupported Anktiva cancer cure claims. Company implemented corrective measures while reporting 750% unit volume growth and $38.29M quarterly revenue.
IBRXsales growthregulatory compliance
The Motley FoolThe Motley Fool··James Brumley

ImmunityBio Surges 11% on First Asian Approval for Bladder Cancer Drug

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.
IBRXAsia-Pacific expansionbladder cancer
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on NCCN Bladder Cancer Guideline Inclusion for Anktiva

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.
IBRXbladder cancerAnktiva
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges 10% on NK Cell Therapy Manufacturing Milestone

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.
IBRXBBPclinical trialbladder cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Urogen Pharma Ltd.

Bladder Cancer Survey Reveals High Recurrence Fear, Procedural Burden Among Patients

BCAN survey of 1,100+ bladder cancer patients shows 80% experience recurrence fear, exceeding 90% in under-50 cohort. UroGen emphasizes need for treatments balancing tumor control with quality of life.
URGNquality of lifebladder cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Bladder Cancer Advocacy Network (Bcan)

Bladder Cancer Patients Face Diagnosis Delays, Support Gaps Despite Treatment Advances

Survey of 1,100+ bladder cancer patients reveals 45% of women misdiagnosed as UTIs, 41% lack mental health support, and financial barriers limit treatment access.
JNJURGNbladder cancerpatient survey
BenzingaBenzinga··Vandana Singh

ImmunityBio Surpasses Enrollment Target in Pivotal Cancer Study as Anktiva Sales Accelerate

ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.
IBRXFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

ImmunityBio Expands European Presence With 85-Person Sales Team for Bladder Cancer Drug

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.
IBRXEuropean expansionbladder cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Therapeutics to Present TARA-002 Data at Major Medical Conferences

Protara Therapeutics will present TARA-002 Phase 2 interim data at ASCO GU Symposium, showcasing results for BCG-unresponsive bladder cancer treatment.
TARAinvestor conferencebladder cancer
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer